At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 126 enrolled
Drug / intervention
placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IIB Trial of G-2535 (Unconjugated Isoflavones-100) in Women at High Risk for Breast Cancer
In Brief
A Phase 2 clinical trial evaluating placebo, genistein, and 1 other intervention for Breast Cancer. Completed, enrolled 126 participants across 1 site.
Detailed Summary
This randomized phase II trial is studying how well genistein works in preventing breast cancer in women at high risk for breast cancer. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of genistein may prevent breast cancer in women at high risk for breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedFeb 2006
Primary CompletionMar 2009
Study CompletionJul 2009
TodayJul 2026
First PostedFeb 13, 2006
Enrollment StartJan 1, 2006
Primary CompletionMar 1, 2009
Study CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 20.4 years ago
Interventions
placebodrug
Given orally
genisteindrug
Given orally
laboratory biomarker analysisother
Correlative studies